Publications by authors named "A Cliff"
Objective: To assess the utility of tumor-intrinsic and cancer-associated fibroblast (CAF) subtypes of pancreatic ductal adenocarcinoma (PDAC) in predicting response to neoadjuvant therapy (NAT) and overall survival (OS).
Background: PDAC remains a deadly disease with limited treatment options, and both the tumor as well as the microenvironment play an important role in pathogenesis. Gene expression-based tumor-intrinsic subtypes (classical and basal-like) have been shown to predict outcomes, but tumor microenvironment subtypes are still evolving.
Article Synopsis
- Researchers have identified distinct subpopulations of cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma using single-cell RNA sequencing, but their clinical importance was uncertain.
- They developed a classifier named DeCAF to classify CAF subtypes based on RNA sequencing data, which has been validated in various cancer types and shown to have unique histological features and prognostic value.
- DeCAF provides a reliable method to understand CAF roles in cancer, assisting in the development of targeted therapies by distinguishing between permissive and restraining CAF subtypes.
Alternatively spliced tissue factor (asTF) promotes the progression of pancreatic ductal adenocarcinoma (PDAC) by activating β1-integrins on PDAC cell surfaces. hRabMab1, a first-in-class humanized inhibitory anti-asTF antibody we recently developed, can suppress PDAC primary tumor growth as a single agent. Whether hRabMab1 has the potential to suppress metastases in PDAC is unknown.
View Article and Find Full Text PDF